 Douglas Seals
Concepts (735)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aging | 184 | 2023 | 1670 | 23.340 |
Why?
| | Endothelium, Vascular | 82 | 2023 | 907 | 16.050 |
Why?
| | Vascular Stiffness | 41 | 2023 | 425 | 10.240 |
Why?
| | Exercise | 94 | 2023 | 1657 | 9.410 |
Why?
| | Oxidative Stress | 62 | 2023 | 1178 | 9.320 |
Why?
| | Vasodilation | 57 | 2022 | 457 | 7.480 |
Why?
| | Arteries | 31 | 2023 | 250 | 6.960 |
Why?
| | Brachial Artery | 38 | 2022 | 181 | 6.940 |
Why?
| | Sympathetic Nervous System | 66 | 2023 | 171 | 6.650 |
Why?
| | Blood Pressure | 98 | 2023 | 1664 | 6.500 |
Why?
| | Carotid Arteries | 25 | 2021 | 184 | 4.530 |
Why?
| | Biomedical Research | 10 | 2023 | 612 | 4.480 |
Why?
| | Writing | 7 | 2023 | 88 | 4.410 |
Why?
| | Aorta | 17 | 2023 | 367 | 4.260 |
Why?
| | Vascular Diseases | 15 | 2023 | 241 | 4.110 |
Why?
| | Antioxidants | 24 | 2023 | 564 | 3.760 |
Why?
| | Regional Blood Flow | 35 | 2020 | 418 | 3.710 |
Why?
| | Nitric Oxide | 33 | 2023 | 892 | 3.650 |
Why?
| | Cardiovascular Diseases | 28 | 2023 | 1798 | 3.590 |
Why?
| | Physical Endurance | 46 | 2016 | 231 | 3.450 |
Why?
| | Sodium Nitrite | 8 | 2021 | 36 | 3.390 |
Why?
| | Publishing | 5 | 2023 | 131 | 3.360 |
Why?
| | Heart Rate | 80 | 2023 | 729 | 3.230 |
Why?
| | Resistance Training | 5 | 2023 | 120 | 3.170 |
Why?
| | Endothelial Cells | 20 | 2023 | 732 | 3.090 |
Why?
| | Aged | 163 | 2023 | 19657 | 3.080 |
Why?
| | Mitochondria | 9 | 2023 | 786 | 2.810 |
Why?
| | Caloric Restriction | 10 | 2021 | 89 | 2.770 |
Why?
| | Middle Aged | 183 | 2023 | 27617 | 2.690 |
Why?
| | Postmenopause | 24 | 2023 | 305 | 2.680 |
Why?
| | Hypertension | 22 | 2023 | 1203 | 2.660 |
Why?
| | Dietary Supplements | 19 | 2023 | 467 | 2.640 |
Why?
| | Blood Vessels | 6 | 2020 | 187 | 2.630 |
Why?
| | Physical Exertion | 34 | 2014 | 222 | 2.490 |
Why?
| | Pulse Wave Analysis | 20 | 2023 | 216 | 2.380 |
Why?
| | Male | 242 | 2023 | 57801 | 2.350 |
Why?
| | Ascorbic Acid | 16 | 2023 | 120 | 2.300 |
Why?
| | Nitric Oxide Synthase Type III | 13 | 2020 | 198 | 2.300 |
Why?
| | Humans | 328 | 2024 | 118974 | 2.290 |
Why?
| | Inflammation | 23 | 2023 | 2566 | 2.280 |
Why?
| | Diet, Sodium-Restricted | 7 | 2020 | 34 | 2.280 |
Why?
| | Physical Fitness | 19 | 2013 | 179 | 2.260 |
Why?
| | Muscles | 32 | 2023 | 333 | 2.230 |
Why?
| | Physical Conditioning, Animal | 10 | 2021 | 204 | 2.210 |
Why?
| | Exercise Tolerance | 8 | 2023 | 233 | 2.150 |
Why?
| | Cardiovascular Physiological Phenomena | 13 | 2019 | 40 | 2.130 |
Why?
| | Oxygen Consumption | 43 | 2023 | 586 | 2.110 |
Why?
| | NF-kappa B | 9 | 2015 | 670 | 2.100 |
Why?
| | Methylamines | 5 | 2022 | 32 | 2.080 |
Why?
| | Peer Review | 4 | 2023 | 40 | 2.080 |
Why?
| | Superoxides | 16 | 2022 | 221 | 2.070 |
Why?
| | Baroreflex | 14 | 2016 | 53 | 1.960 |
Why?
| | Acetylcholine | 12 | 2023 | 208 | 1.910 |
Why?
| | Adult | 190 | 2023 | 31512 | 1.810 |
Why?
| | Vasodilator Agents | 11 | 2017 | 328 | 1.790 |
Why?
| | Diet, Western | 3 | 2022 | 69 | 1.760 |
Why?
| | Mice | 49 | 2023 | 15520 | 1.740 |
Why?
| | Female | 168 | 2023 | 61565 | 1.700 |
Why?
| | Heart | 16 | 2018 | 631 | 1.680 |
Why?
| | Animals | 78 | 2023 | 33381 | 1.650 |
Why?
| | Adipose Tissue | 17 | 2018 | 606 | 1.650 |
Why?
| | Norepinephrine | 28 | 2011 | 212 | 1.590 |
Why?
| | Physiology | 3 | 2023 | 10 | 1.570 |
Why?
| | Salicylates | 5 | 2015 | 32 | 1.500 |
Why?
| | Respiratory Muscles | 5 | 2023 | 36 | 1.500 |
Why?
| | Forearm | 18 | 2023 | 117 | 1.500 |
Why?
| | NADPH Oxidases | 13 | 2020 | 138 | 1.470 |
Why?
| | Cellular Senescence | 6 | 2023 | 151 | 1.440 |
Why?
| | Healthy Aging | 3 | 2021 | 18 | 1.430 |
Why?
| | Vascular Resistance | 19 | 2012 | 356 | 1.400 |
Why?
| | Research Personnel | 4 | 2023 | 158 | 1.390 |
Why?
| | Motor Activity | 7 | 2021 | 660 | 1.350 |
Why?
| | Estrogens | 8 | 2023 | 328 | 1.330 |
Why?
| | Reactive Oxygen Species | 13 | 2023 | 576 | 1.320 |
Why?
| | Double-Blind Method | 15 | 2023 | 1687 | 1.280 |
Why?
| | Mice, Inbred C57BL | 22 | 2023 | 4908 | 1.280 |
Why?
| | Healthy Lifestyle | 2 | 2018 | 33 | 1.280 |
Why?
| | Tyrosine | 14 | 2020 | 233 | 1.270 |
Why?
| | Aorta, Thoracic | 4 | 2014 | 248 | 1.230 |
Why?
| | Geriatrics | 4 | 2015 | 68 | 1.200 |
Why?
| | Muscle, Skeletal | 20 | 2023 | 1515 | 1.200 |
Why?
| | Autonomic Nervous System | 10 | 2008 | 66 | 1.200 |
Why?
| | Femoral Artery | 11 | 2013 | 175 | 1.190 |
Why?
| | NAD | 5 | 2023 | 67 | 1.180 |
Why?
| | Smoking Water Pipes | 2 | 2023 | 5 | 1.170 |
Why?
| | Water Pipe Smoking | 2 | 2023 | 6 | 1.170 |
Why?
| | Estrogen Replacement Therapy | 12 | 2013 | 117 | 1.160 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 304 | 1.150 |
Why?
| | Age Factors | 26 | 2021 | 2995 | 1.140 |
Why?
| | Metabolomics | 4 | 2021 | 550 | 1.090 |
Why?
| | Longevity | 4 | 2015 | 151 | 1.070 |
Why?
| | Vasoconstriction | 6 | 2017 | 213 | 1.070 |
Why?
| | Receptors, Adrenergic, beta | 6 | 2008 | 144 | 1.060 |
Why?
| | Inflammation Mediators | 5 | 2018 | 502 | 1.050 |
Why?
| | Cross-Over Studies | 10 | 2023 | 456 | 1.040 |
Why?
| | Cyclic N-Oxides | 8 | 2020 | 31 | 1.020 |
Why?
| | Elasticity | 11 | 2017 | 193 | 1.010 |
Why?
| | Curcumin | 2 | 2017 | 33 | 1.010 |
Why?
| | Gastrointestinal Microbiome | 3 | 2020 | 548 | 1.000 |
Why?
| | Drinking Water | 2 | 2022 | 68 | 0.990 |
Why?
| | Habits | 7 | 2017 | 38 | 0.990 |
Why?
| | Interleukin-1 | 5 | 2022 | 980 | 0.970 |
Why?
| | Body Temperature Regulation | 7 | 2007 | 73 | 0.950 |
Why?
| | Trehalose | 4 | 2017 | 35 | 0.940 |
Why?
| | Transcriptome | 3 | 2023 | 756 | 0.910 |
Why?
| | Young Adult | 27 | 2023 | 10793 | 0.900 |
Why?
| | Human Umbilical Vein Endothelial Cells | 3 | 2021 | 95 | 0.900 |
Why?
| | Fenofibrate | 2 | 2013 | 24 | 0.900 |
Why?
| | Vaping | 1 | 2023 | 51 | 0.890 |
Why?
| | Cardiorespiratory Fitness | 2 | 2021 | 39 | 0.890 |
Why?
| | Elastin | 6 | 2023 | 77 | 0.880 |
Why?
| | Lyases | 1 | 2022 | 9 | 0.870 |
Why?
| | Muscle Strength | 6 | 2023 | 283 | 0.870 |
Why?
| | Body Composition | 27 | 2012 | 653 | 0.860 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2023 | 81 | 0.860 |
Why?
| | Hypolipidemic Agents | 2 | 2013 | 86 | 0.860 |
Why?
| | Nicotinamide Mononucleotide | 3 | 2023 | 12 | 0.850 |
Why?
| | Sodium, Dietary | 4 | 2013 | 43 | 0.850 |
Why?
| | Hemodynamics | 17 | 2023 | 1004 | 0.850 |
Why?
| | Research Design | 4 | 2022 | 969 | 0.850 |
Why?
| | Compliance | 12 | 2017 | 44 | 0.840 |
Why?
| | Obesity | 14 | 2023 | 2746 | 0.840 |
Why?
| | Rest | 12 | 2007 | 104 | 0.830 |
Why?
| | Stress, Physiological | 12 | 2017 | 415 | 0.820 |
Why?
| | Aortitis | 2 | 2011 | 7 | 0.820 |
Why?
| | Speech | 1 | 2022 | 76 | 0.820 |
Why?
| | Spirostans | 1 | 2021 | 4 | 0.810 |
Why?
| | Breathing Exercises | 1 | 2021 | 22 | 0.800 |
Why?
| | Inhalation | 1 | 2021 | 27 | 0.800 |
Why?
| | Spin Labels | 8 | 2020 | 50 | 0.800 |
Why?
| | Isometric Contraction | 14 | 1996 | 155 | 0.790 |
Why?
| | Superoxide Dismutase | 9 | 2016 | 339 | 0.780 |
Why?
| | Running | 15 | 2017 | 227 | 0.770 |
Why?
| | Comprehension | 1 | 2022 | 163 | 0.770 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2021 | 1171 | 0.770 |
Why?
| | Reference Values | 26 | 2021 | 774 | 0.770 |
Why?
| | Biomarkers | 18 | 2023 | 3588 | 0.760 |
Why?
| | Dementia | 1 | 2023 | 208 | 0.750 |
Why?
| | Doxorubicin | 2 | 2021 | 302 | 0.750 |
Why?
| | Cardiac Output | 15 | 2004 | 147 | 0.750 |
Why?
| | Fasting | 2 | 2020 | 264 | 0.750 |
Why?
| | Cytokines | 10 | 2019 | 1900 | 0.740 |
Why?
| | Career Choice | 1 | 2022 | 192 | 0.730 |
Why?
| | Nitroglycerin | 3 | 2020 | 24 | 0.720 |
Why?
| | Frailty | 1 | 2022 | 116 | 0.720 |
Why?
| | Niacinamide | 3 | 2022 | 70 | 0.720 |
Why?
| | Overweight | 3 | 2009 | 502 | 0.710 |
Why?
| | Life Style | 13 | 2017 | 430 | 0.710 |
Why?
| | Leg | 12 | 2007 | 234 | 0.710 |
Why?
| | Mentoring | 1 | 2021 | 101 | 0.710 |
Why?
| | Autophagy | 3 | 2017 | 315 | 0.700 |
Why?
| | Lipids | 6 | 2018 | 607 | 0.700 |
Why?
| | Physical Conditioning, Human | 1 | 2019 | 28 | 0.700 |
Why?
| | Adolescent | 45 | 2023 | 18480 | 0.700 |
Why?
| | Nitrites | 3 | 2014 | 81 | 0.700 |
Why?
| | Sex Characteristics | 13 | 2011 | 671 | 0.690 |
Why?
| | Energy Metabolism | 8 | 2007 | 767 | 0.690 |
Why?
| | Cardiovascular System | 10 | 2020 | 127 | 0.680 |
Why?
| | Physical Education and Training | 14 | 2004 | 62 | 0.680 |
Why?
| | Isoproterenol | 4 | 2007 | 125 | 0.680 |
Why?
| | Sirtuin 1 | 3 | 2016 | 29 | 0.670 |
Why?
| | Adrenergic beta-Agonists | 4 | 2007 | 132 | 0.660 |
Why?
| | Adaptation, Physiological | 8 | 2019 | 502 | 0.650 |
Why?
| | Amino Acids | 2 | 2019 | 465 | 0.640 |
Why?
| | Health Status | 3 | 2019 | 726 | 0.640 |
Why?
| | Health Personnel | 1 | 2024 | 588 | 0.630 |
Why?
| | Glycation End Products, Advanced | 3 | 2013 | 67 | 0.630 |
Why?
| | Body Constitution | 4 | 2005 | 47 | 0.630 |
Why?
| | Blood Volume | 8 | 1998 | 58 | 0.630 |
Why?
| | Lipoproteins, LDL | 10 | 2023 | 138 | 0.620 |
Why?
| | Vagus Nerve | 6 | 2005 | 80 | 0.620 |
Why?
| | Tunica Intima | 7 | 2006 | 78 | 0.610 |
Why?
| | Sodium Chloride, Dietary | 3 | 2019 | 49 | 0.600 |
Why?
| | Extracellular Matrix | 1 | 2021 | 446 | 0.600 |
Why?
| | Nitroprusside | 5 | 2011 | 88 | 0.600 |
Why?
| | Muscle, Smooth, Vascular | 6 | 2017 | 454 | 0.600 |
Why?
| | Serine | 2 | 2015 | 138 | 0.580 |
Why?
| | Transcription Factor RelA | 4 | 2011 | 82 | 0.580 |
Why?
| | Diet Therapy | 1 | 2016 | 38 | 0.570 |
Why?
| | Models, Animal | 5 | 2021 | 363 | 0.570 |
Why?
| | Muscle Contraction | 13 | 2003 | 413 | 0.570 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2022 | 2062 | 0.570 |
Why?
| | Glucose | 3 | 2019 | 953 | 0.560 |
Why?
| | Time Factors | 21 | 2021 | 6412 | 0.560 |
Why?
| | Estradiol | 3 | 2021 | 476 | 0.550 |
Why?
| | Primary Prevention | 1 | 2018 | 185 | 0.550 |
Why?
| | Blood Glucose | 10 | 2017 | 1939 | 0.540 |
Why?
| | Cross-Sectional Studies | 21 | 2020 | 4552 | 0.540 |
Why?
| | Basal Metabolism | 3 | 2004 | 50 | 0.530 |
Why?
| | Epinephrine | 13 | 2007 | 167 | 0.530 |
Why?
| | Renal Insufficiency, Chronic | 5 | 2023 | 589 | 0.520 |
Why?
| | Risk Factors | 19 | 2021 | 9000 | 0.520 |
Why?
| | Proteome | 1 | 2018 | 353 | 0.510 |
Why?
| | Collagen | 3 | 2021 | 433 | 0.510 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 16 | 0.510 |
Why?
| | Reflex | 6 | 2001 | 64 | 0.510 |
Why?
| | AMP-Activated Protein Kinases | 3 | 2017 | 178 | 0.500 |
Why?
| | Body Mass Index | 16 | 2015 | 2092 | 0.500 |
Why?
| | Geriatric Assessment | 2 | 2015 | 185 | 0.490 |
Why?
| | Nitrates | 4 | 2022 | 78 | 0.490 |
Why?
| | Ubiquinone | 1 | 2014 | 25 | 0.490 |
Why?
| | Endothelium | 1 | 2014 | 120 | 0.490 |
Why?
| | Atherosclerosis | 1 | 2018 | 345 | 0.480 |
Why?
| | Premenopause | 8 | 2016 | 108 | 0.480 |
Why?
| | Niacin | 1 | 2013 | 20 | 0.480 |
Why?
| | Bufanolides | 1 | 2013 | 4 | 0.470 |
Why?
| | Vitamin B Complex | 1 | 2013 | 37 | 0.470 |
Why?
| | Hindlimb | 1 | 2014 | 137 | 0.460 |
Why?
| | Spermidine | 1 | 2013 | 12 | 0.460 |
Why?
| | Diet | 5 | 2016 | 1153 | 0.460 |
Why?
| | Locomotion | 1 | 2014 | 83 | 0.460 |
Why?
| | Organophosphorus Compounds | 1 | 2014 | 76 | 0.460 |
Why?
| | Eating | 2 | 2007 | 369 | 0.460 |
Why?
| | Exercise Test | 12 | 2021 | 551 | 0.450 |
Why?
| | Aortic Diseases | 1 | 2014 | 94 | 0.450 |
Why?
| | Hand Strength | 3 | 2023 | 99 | 0.450 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 199 | 0.450 |
Why?
| | Nitric Oxide Donors | 1 | 2012 | 16 | 0.440 |
Why?
| | Arm | 7 | 2008 | 106 | 0.430 |
Why?
| | Cognition | 2 | 2020 | 1024 | 0.430 |
Why?
| | Carotid Artery Diseases | 2 | 2010 | 58 | 0.430 |
Why?
| | Obesity, Abdominal | 1 | 2012 | 39 | 0.420 |
Why?
| | Dose-Response Relationship, Drug | 8 | 2015 | 1945 | 0.410 |
Why?
| | Allopurinol | 2 | 2016 | 82 | 0.410 |
Why?
| | I-kappa B Proteins | 2 | 2009 | 80 | 0.410 |
Why?
| | Postural Balance | 1 | 2014 | 184 | 0.410 |
Why?
| | Neurodegenerative Diseases | 2 | 2023 | 99 | 0.410 |
Why?
| | C-Reactive Protein | 3 | 2022 | 360 | 0.400 |
Why?
| | Adrenal Glands | 3 | 2000 | 72 | 0.400 |
Why?
| | Arteritis | 1 | 2011 | 27 | 0.400 |
Why?
| | Athletic Performance | 2 | 2012 | 46 | 0.390 |
Why?
| | Cholesterol, LDL | 5 | 2008 | 316 | 0.380 |
Why?
| | Oxidants | 1 | 2011 | 122 | 0.380 |
Why?
| | Behavior, Animal | 1 | 2014 | 486 | 0.380 |
Why?
| | Ganglionic Blockers | 6 | 2008 | 6 | 0.380 |
Why?
| | Athletes | 2 | 2022 | 353 | 0.370 |
Why?
| | Pressoreceptors | 5 | 1990 | 18 | 0.360 |
Why?
| | Hot Temperature | 5 | 1993 | 334 | 0.360 |
Why?
| | Forkhead Transcription Factors | 1 | 2011 | 182 | 0.360 |
Why?
| | Metabolome | 3 | 2018 | 296 | 0.360 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 1974 | 0.360 |
Why?
| | Analysis of Variance | 7 | 2011 | 1293 | 0.360 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2010 | 164 | 0.350 |
Why?
| | Peroxidase | 1 | 2010 | 170 | 0.350 |
Why?
| | Anti-Bacterial Agents | 1 | 2019 | 1510 | 0.350 |
Why?
| | Receptors, Adrenergic, beta-2 | 2 | 2007 | 44 | 0.350 |
Why?
| | Biological Availability | 4 | 2021 | 126 | 0.340 |
Why?
| | Blood Circulation | 4 | 2021 | 36 | 0.340 |
Why?
| | Interleukins | 2 | 2022 | 242 | 0.340 |
Why?
| | Ultrasonography | 9 | 2017 | 716 | 0.340 |
Why?
| | Oxygen | 11 | 2022 | 854 | 0.330 |
Why?
| | Systole | 5 | 2020 | 168 | 0.330 |
Why?
| | Vitamin D Deficiency | 1 | 2010 | 162 | 0.330 |
Why?
| | Vitamin D | 2 | 2017 | 354 | 0.330 |
Why?
| | Upper Extremity | 1 | 2009 | 81 | 0.330 |
Why?
| | Administration, Oral | 5 | 2015 | 756 | 0.330 |
Why?
| | Uric Acid | 1 | 2012 | 354 | 0.330 |
Why?
| | Signal Transduction | 6 | 2014 | 4709 | 0.330 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 509 | 0.330 |
Why?
| | NG-Nitroarginine Methyl Ester | 4 | 2013 | 48 | 0.330 |
Why?
| | Healthy Volunteers | 3 | 2018 | 201 | 0.330 |
Why?
| | Collagen Type I | 3 | 2014 | 114 | 0.330 |
Why?
| | Ventricular Function, Left | 3 | 2003 | 468 | 0.330 |
Why?
| | Endothelin-1 | 2 | 2009 | 168 | 0.320 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 43 | 0.320 |
Why?
| | Peroneal Nerve | 5 | 2000 | 19 | 0.320 |
Why?
| | Sports | 5 | 2003 | 194 | 0.320 |
Why?
| | Abdomen | 5 | 2004 | 110 | 0.310 |
Why?
| | Posture | 5 | 1997 | 158 | 0.310 |
Why?
| | Phosphorylation | 6 | 2013 | 1633 | 0.310 |
Why?
| | Infusions, Intravenous | 5 | 2014 | 380 | 0.310 |
Why?
| | Hypoxia | 6 | 1999 | 963 | 0.300 |
Why?
| | Human Experimentation | 1 | 2007 | 12 | 0.300 |
Why?
| | Pilot Projects | 3 | 2020 | 1419 | 0.300 |
Why?
| | Adiposity | 1 | 2012 | 516 | 0.300 |
Why?
| | Acetophenones | 3 | 2019 | 14 | 0.300 |
Why?
| | Trimethaphan | 5 | 2005 | 5 | 0.300 |
Why?
| | Treatment Outcome | 6 | 2021 | 9342 | 0.300 |
Why?
| | Swimming | 5 | 2002 | 46 | 0.290 |
Why?
| | Phenylephrine | 5 | 2005 | 85 | 0.290 |
Why?
| | Tunica Media | 3 | 2001 | 36 | 0.290 |
Why?
| | Interleukin-6 | 3 | 2020 | 688 | 0.290 |
Why?
| | Enzyme Inhibitors | 4 | 2016 | 827 | 0.290 |
Why?
| | Energy Intake | 5 | 2020 | 447 | 0.290 |
Why?
| | Regression Analysis | 9 | 2011 | 983 | 0.290 |
Why?
| | Nitric Oxide Synthase | 3 | 2014 | 225 | 0.280 |
Why?
| | Cells, Cultured | 4 | 2021 | 4077 | 0.280 |
Why?
| | Proteins | 3 | 2009 | 938 | 0.280 |
Why?
| | Gene Expression Regulation | 3 | 2017 | 2445 | 0.280 |
Why?
| | Fatty Acids | 2 | 2019 | 407 | 0.280 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 527 | 0.270 |
Why?
| | Recovery of Function | 4 | 2017 | 604 | 0.270 |
Why?
| | Microcirculation | 2 | 2019 | 155 | 0.270 |
Why?
| | Thermogenesis | 1 | 2005 | 43 | 0.270 |
Why?
| | Colorado | 5 | 2021 | 4196 | 0.270 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2007 | 290 | 0.270 |
Why?
| | Carbon Dioxide | 3 | 2023 | 230 | 0.270 |
Why?
| | Cell Nucleus | 1 | 2008 | 580 | 0.260 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 2 | 2011 | 42 | 0.260 |
Why?
| | Arginine | 1 | 2006 | 249 | 0.260 |
Why?
| | American Heart Association | 2 | 2020 | 270 | 0.260 |
Why?
| | MicroRNAs | 1 | 2011 | 637 | 0.260 |
Why?
| | Electrocardiography | 8 | 2005 | 556 | 0.250 |
Why?
| | Preventive Medicine | 2 | 2015 | 39 | 0.250 |
Why?
| | Weight Loss | 2 | 2008 | 655 | 0.250 |
Why?
| | Apigenin | 1 | 2023 | 3 | 0.240 |
Why?
| | Flavonols | 1 | 2023 | 10 | 0.240 |
Why?
| | Skin | 4 | 2019 | 657 | 0.240 |
Why?
| | Respiratory Therapy | 1 | 2023 | 19 | 0.240 |
Why?
| | Lactates | 7 | 2007 | 87 | 0.230 |
Why?
| | Xanthine Oxidase | 3 | 2009 | 80 | 0.230 |
Why?
| | Tissue Culture Techniques | 2 | 2014 | 67 | 0.230 |
Why?
| | Blueberry Plants | 1 | 2023 | 8 | 0.230 |
Why?
| | Hand | 8 | 1994 | 137 | 0.230 |
Why?
| | Blood Flow Velocity | 6 | 2019 | 327 | 0.230 |
Why?
| | Cholesterol | 5 | 1997 | 373 | 0.220 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2014 | 180 | 0.220 |
Why?
| | Authorship | 1 | 2023 | 36 | 0.220 |
Why?
| | Anthropometry | 3 | 2011 | 194 | 0.220 |
Why?
| | Aged, 80 and over | 11 | 2023 | 6561 | 0.220 |
Why?
| | Myocardium | 5 | 2010 | 970 | 0.220 |
Why?
| | Acetylene | 2 | 2003 | 3 | 0.220 |
Why?
| | Exercise Therapy | 6 | 2002 | 355 | 0.220 |
Why?
| | Terminology as Topic | 1 | 2023 | 211 | 0.220 |
Why?
| | Supine Position | 6 | 1999 | 39 | 0.210 |
Why?
| | Sugars | 1 | 2022 | 32 | 0.210 |
Why?
| | Fibrinolysis | 2 | 2008 | 159 | 0.210 |
Why?
| | Adrenal Medulla | 1 | 2002 | 7 | 0.210 |
Why?
| | Respiration | 7 | 1998 | 183 | 0.210 |
Why?
| | Citrulline | 1 | 2022 | 41 | 0.210 |
Why?
| | Coronary Disease | 6 | 1998 | 356 | 0.210 |
Why?
| | Apoptosis | 1 | 2011 | 2484 | 0.210 |
Why?
| | Sirolimus | 3 | 2021 | 195 | 0.200 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 76 | 0.200 |
Why?
| | Case-Control Studies | 3 | 2020 | 3171 | 0.200 |
Why?
| | Cyclooxygenase 2 | 2 | 2014 | 168 | 0.200 |
Why?
| | Body Weight | 10 | 2019 | 934 | 0.200 |
Why?
| | Weight Gain | 1 | 2004 | 493 | 0.200 |
Why?
| | Nicotine | 1 | 2023 | 276 | 0.200 |
Why?
| | Progesterone | 1 | 2002 | 242 | 0.200 |
Why?
| | I-kappa B Kinase | 2 | 2011 | 50 | 0.200 |
Why?
| | Fatty Liver | 1 | 2023 | 253 | 0.200 |
Why?
| | Veins | 4 | 2009 | 60 | 0.190 |
Why?
| | Repetitive Sequences, Nucleic Acid | 1 | 2021 | 103 | 0.190 |
Why?
| | Free Radical Scavengers | 2 | 2013 | 88 | 0.190 |
Why?
| | Manuscripts as Topic | 1 | 2000 | 2 | 0.190 |
Why?
| | Knee | 1 | 2000 | 52 | 0.190 |
Why?
| | DNA Transposable Elements | 1 | 2021 | 102 | 0.190 |
Why?
| | Lipocalin-2 | 1 | 2020 | 64 | 0.190 |
Why?
| | Lung | 4 | 1999 | 3664 | 0.190 |
Why?
| | Myocardial Reperfusion Injury | 2 | 2011 | 105 | 0.190 |
Why?
| | Brain | 5 | 2023 | 2490 | 0.180 |
Why?
| | Insulin | 10 | 2022 | 2162 | 0.180 |
Why?
| | Fibrinogen | 2 | 1998 | 161 | 0.180 |
Why?
| | Mentors | 1 | 2021 | 166 | 0.180 |
Why?
| | Triglycerides | 4 | 2017 | 519 | 0.180 |
Why?
| | RNA, Untranslated | 1 | 2021 | 115 | 0.180 |
Why?
| | Functional Food | 1 | 2019 | 3 | 0.180 |
Why?
| | Menopause | 2 | 2006 | 266 | 0.180 |
Why?
| | Drug Monitoring | 1 | 2021 | 187 | 0.180 |
Why?
| | Waist-Hip Ratio | 2 | 2012 | 31 | 0.180 |
Why?
| | Pulmonary Circulation | 1 | 2001 | 424 | 0.180 |
Why?
| | Adrenergic alpha-Agonists | 3 | 2005 | 31 | 0.170 |
Why?
| | Cold Temperature | 6 | 1996 | 132 | 0.170 |
Why?
| | Adipose Tissue, White | 1 | 2019 | 35 | 0.170 |
Why?
| | Adipokines | 1 | 2019 | 46 | 0.170 |
Why?
| | Rats | 11 | 2015 | 5392 | 0.170 |
Why?
| | Fluorescent Antibody Technique | 3 | 2009 | 410 | 0.170 |
Why?
| | Social Class | 1 | 2001 | 218 | 0.170 |
Why?
| | Transforming Growth Factor beta | 2 | 2012 | 462 | 0.170 |
Why?
| | NF-KappaB Inhibitor alpha | 2 | 2009 | 52 | 0.170 |
Why?
| | Lower Body Negative Pressure | 4 | 1992 | 11 | 0.170 |
Why?
| | Stroke Volume | 7 | 1998 | 513 | 0.170 |
Why?
| | Cohort Studies | 5 | 2013 | 5116 | 0.160 |
Why?
| | Guidelines as Topic | 1 | 2020 | 262 | 0.160 |
Why?
| | Pyridinium Compounds | 1 | 2018 | 14 | 0.160 |
Why?
| | Linear Models | 2 | 2012 | 827 | 0.160 |
Why?
| | Methionine | 1 | 2018 | 145 | 0.160 |
Why?
| | Leptin | 5 | 2019 | 231 | 0.160 |
Why?
| | Adipocytes | 1 | 2019 | 199 | 0.160 |
Why?
| | Cardiology | 1 | 2020 | 272 | 0.150 |
Why?
| | Metabolic Syndrome | 2 | 2019 | 394 | 0.150 |
Why?
| | Unfolded Protein Response | 2 | 2017 | 46 | 0.150 |
Why?
| | Extremities | 1 | 1998 | 113 | 0.150 |
Why?
| | Stress, Psychological | 3 | 1995 | 972 | 0.150 |
Why?
| | Calcitriol | 1 | 2017 | 55 | 0.150 |
Why?
| | Cholecalciferol | 1 | 2017 | 51 | 0.150 |
Why?
| | Neuromuscular Junction | 2 | 1995 | 53 | 0.150 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 175 | 0.150 |
Why?
| | Walking | 3 | 2011 | 415 | 0.150 |
Why?
| | Carotid Artery, Common | 1 | 2017 | 30 | 0.150 |
Why?
| | Gene Regulatory Networks | 1 | 2018 | 239 | 0.150 |
Why?
| | Cognitive Dysfunction | 1 | 2021 | 301 | 0.140 |
Why?
| | Kidney | 5 | 2017 | 1353 | 0.140 |
Why?
| | Congresses as Topic | 1 | 2018 | 204 | 0.140 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2017 | 97 | 0.140 |
Why?
| | Education, Graduate | 1 | 2016 | 36 | 0.140 |
Why?
| | Students, Health Occupations | 1 | 2016 | 23 | 0.140 |
Why?
| | Blood Coagulation | 1 | 1998 | 219 | 0.140 |
Why?
| | Methemoglobin | 1 | 2015 | 22 | 0.140 |
Why?
| | Age Distribution | 1 | 1997 | 362 | 0.140 |
Why?
| | Hemostasis | 2 | 1998 | 70 | 0.140 |
Why?
| | Risk Assessment | 2 | 2018 | 3057 | 0.140 |
Why?
| | Program Development | 1 | 2018 | 357 | 0.130 |
Why?
| | Myocardial Contraction | 3 | 1988 | 339 | 0.130 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 1995 | 49 | 0.130 |
Why?
| | Anaerobic Threshold | 3 | 2008 | 21 | 0.130 |
Why?
| | Lipid Metabolism | 1 | 2018 | 477 | 0.130 |
Why?
| | NADPH Oxidase 4 | 1 | 2014 | 10 | 0.130 |
Why?
| | Urinalysis | 1 | 2015 | 68 | 0.130 |
Why?
| | Hyperuricemia | 1 | 2016 | 134 | 0.130 |
Why?
| | Src Homology 2 Domain-Containing, Transforming Protein 1 | 1 | 2014 | 10 | 0.130 |
Why?
| | Shc Signaling Adaptor Proteins | 1 | 2014 | 10 | 0.130 |
Why?
| | Rotenone | 1 | 2014 | 4 | 0.130 |
Why?
| | Mitochondrial Proteins | 1 | 2016 | 226 | 0.130 |
Why?
| | Neurons | 2 | 1995 | 1345 | 0.130 |
Why?
| | Skinfold Thickness | 4 | 1999 | 46 | 0.130 |
Why?
| | Rejuvenation | 1 | 2014 | 14 | 0.120 |
Why?
| | Nutritional Status | 1 | 2016 | 300 | 0.120 |
Why?
| | Disease Models, Animal | 3 | 2015 | 3730 | 0.120 |
Why?
| | Glomerular Filtration Rate | 1 | 2017 | 683 | 0.120 |
Why?
| | Mobility Limitation | 1 | 2014 | 62 | 0.120 |
Why?
| | Cell Cycle | 1 | 2016 | 550 | 0.120 |
Why?
| | Administration, Cutaneous | 1 | 2013 | 119 | 0.120 |
Why?
| | Epidemiology | 1 | 2013 | 15 | 0.120 |
Why?
| | Program Evaluation | 1 | 2018 | 845 | 0.110 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 1994 | 107 | 0.110 |
Why?
| | Cardiotonic Agents | 1 | 2014 | 127 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2012 | 229 | 0.110 |
Why?
| | Multivariate Analysis | 2 | 2012 | 1474 | 0.110 |
Why?
| | Respiratory Mechanics | 1 | 1993 | 60 | 0.110 |
Why?
| | Prospective Studies | 6 | 2021 | 6471 | 0.110 |
Why?
| | Body Temperature | 5 | 1991 | 215 | 0.110 |
Why?
| | Statistics as Topic | 2 | 2011 | 307 | 0.110 |
Why?
| | Diabetic Angiopathies | 1 | 2015 | 260 | 0.110 |
Why?
| | Administration, Sublingual | 1 | 2012 | 14 | 0.110 |
Why?
| | Insulin Resistance | 2 | 2018 | 1180 | 0.110 |
Why?
| | Pyrogallol | 1 | 2012 | 3 | 0.110 |
Why?
| | Catecholamines | 5 | 1996 | 100 | 0.110 |
Why?
| | Mental Processes | 1 | 1992 | 35 | 0.110 |
Why?
| | Aminoimidazole Carboxamide | 1 | 2012 | 11 | 0.110 |
Why?
| | Hypotension | 1 | 1993 | 120 | 0.110 |
Why?
| | Ribonucleotides | 1 | 2012 | 26 | 0.110 |
Why?
| | Pulmonary Gas Exchange | 4 | 2007 | 117 | 0.110 |
Why?
| | Retrospective Studies | 4 | 2022 | 12978 | 0.100 |
Why?
| | Waist Circumference | 1 | 2012 | 130 | 0.100 |
Why?
| | Naphthols | 1 | 2011 | 7 | 0.100 |
Why?
| | Plethysmography | 3 | 2007 | 124 | 0.100 |
Why?
| | Hysterectomy | 1 | 2012 | 117 | 0.100 |
Why?
| | Receptors, Adrenergic, beta-3 | 1 | 2011 | 3 | 0.100 |
Why?
| | Nitroso Compounds | 1 | 2011 | 6 | 0.100 |
Why?
| | United States | 3 | 2020 | 12555 | 0.100 |
Why?
| | Myography | 1 | 2011 | 4 | 0.100 |
Why?
| | Metabolism | 2 | 2001 | 39 | 0.100 |
Why?
| | Chemokine CCL2 | 1 | 2011 | 126 | 0.100 |
Why?
| | Least-Squares Analysis | 1 | 2011 | 73 | 0.100 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 940 | 0.100 |
Why?
| | Forkhead Box Protein O3 | 1 | 2011 | 16 | 0.100 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2010 | 17 | 0.100 |
Why?
| | Diastole | 3 | 2003 | 145 | 0.100 |
Why?
| | Glucose Tolerance Test | 3 | 2018 | 368 | 0.100 |
Why?
| | Endorphins | 1 | 1990 | 7 | 0.100 |
Why?
| | Connective Tissue | 1 | 2010 | 37 | 0.100 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 56 | 0.100 |
Why?
| | Benzamides | 1 | 2011 | 176 | 0.100 |
Why?
| | Mice, Inbred Strains | 1 | 2011 | 405 | 0.100 |
Why?
| | Communication | 1 | 2016 | 761 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2010 | 56 | 0.090 |
Why?
| | Phosphoproteins | 1 | 2012 | 308 | 0.090 |
Why?
| | Decompression | 1 | 1990 | 3 | 0.090 |
Why?
| | Caspases | 1 | 2011 | 269 | 0.090 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4596 | 0.090 |
Why?
| | Lipoproteins, HDL | 3 | 1984 | 82 | 0.090 |
Why?
| | Fibronectins | 1 | 2010 | 114 | 0.090 |
Why?
| | Prediabetic State | 1 | 2013 | 234 | 0.090 |
Why?
| | Curriculum | 1 | 2016 | 910 | 0.090 |
Why?
| | Liver | 2 | 2017 | 1816 | 0.090 |
Why?
| | Prognosis | 1 | 2018 | 3443 | 0.090 |
Why?
| | Acclimatization | 1 | 1990 | 135 | 0.090 |
Why?
| | Sex Factors | 2 | 2011 | 1781 | 0.090 |
Why?
| | Diet Records | 1 | 2009 | 81 | 0.090 |
Why?
| | Cyclooxygenase 1 | 1 | 2009 | 22 | 0.090 |
Why?
| | Subclavian Artery | 1 | 1989 | 31 | 0.090 |
Why?
| | Receptor, Endothelin A | 1 | 2009 | 60 | 0.090 |
Why?
| | Leukocyte Count | 1 | 2010 | 305 | 0.090 |
Why?
| | Blood Pressure Determination | 1 | 2010 | 133 | 0.090 |
Why?
| | Carotid Sinus | 1 | 1988 | 2 | 0.080 |
Why?
| | Arrhythmia, Sinus | 1 | 1988 | 2 | 0.080 |
Why?
| | Homeostasis | 3 | 2021 | 594 | 0.080 |
Why?
| | Probability | 1 | 2010 | 305 | 0.080 |
Why?
| | Biomechanical Phenomena | 1 | 2012 | 683 | 0.080 |
Why?
| | Sulfaphenazole | 1 | 2008 | 3 | 0.080 |
Why?
| | Cytochrome P-450 CYP2C9 | 1 | 2008 | 18 | 0.080 |
Why?
| | omega-N-Methylarginine | 1 | 2008 | 27 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 2 | 2010 | 2478 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 236 | 0.080 |
Why?
| | Aortic Coarctation | 1 | 1989 | 57 | 0.080 |
Why?
| | Tetralogy of Fallot | 1 | 1989 | 79 | 0.080 |
Why?
| | Leukocytes | 1 | 2010 | 290 | 0.080 |
Why?
| | Estrogen Receptor alpha | 1 | 2009 | 126 | 0.080 |
Why?
| | Diet, High-Fat | 2 | 2021 | 247 | 0.080 |
Why?
| | Databases, Factual | 1 | 2013 | 1231 | 0.080 |
Why?
| | Telomere | 1 | 2010 | 204 | 0.080 |
Why?
| | Vasoconstrictor Agents | 2 | 2007 | 122 | 0.080 |
Why?
| | Interferon-gamma | 1 | 2011 | 736 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 412 | 0.080 |
Why?
| | Hyperemia | 1 | 1988 | 43 | 0.080 |
Why?
| | Hyperoxia | 2 | 1999 | 97 | 0.070 |
Why?
| | Catalase | 1 | 2007 | 123 | 0.070 |
Why?
| | Electrophysiology | 3 | 1993 | 204 | 0.070 |
Why?
| | Kinetics | 3 | 1997 | 1624 | 0.070 |
Why?
| | Amidohydrolases | 1 | 2006 | 29 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2674 | 0.070 |
Why?
| | Data Interpretation, Statistical | 1 | 2008 | 336 | 0.070 |
Why?
| | Gene Expression | 1 | 2011 | 1489 | 0.070 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 117 | 0.070 |
Why?
| | Fibroblasts | 1 | 2010 | 842 | 0.070 |
Why?
| | Body Fat Distribution | 1 | 2005 | 45 | 0.070 |
Why?
| | Calorimetry, Indirect | 1 | 2005 | 72 | 0.070 |
Why?
| | Hematocrit | 2 | 1997 | 91 | 0.070 |
Why?
| | Codon | 1 | 2005 | 89 | 0.070 |
Why?
| | Heart Ventricles | 3 | 2003 | 727 | 0.070 |
Why?
| | Dihydroxyphenylalanine | 2 | 1995 | 7 | 0.070 |
Why?
| | Methoxyhydroxyphenylglycol | 2 | 1995 | 11 | 0.070 |
Why?
| | Vital Capacity | 2 | 2000 | 260 | 0.060 |
Why?
| | Erythrocyte Volume | 2 | 1994 | 4 | 0.060 |
Why?
| | Plasma Volume | 2 | 1994 | 13 | 0.060 |
Why?
| | Calorimetry | 1 | 2004 | 59 | 0.060 |
Why?
| | Vasopressins | 1 | 2005 | 64 | 0.060 |
Why?
| | Thigh | 2 | 2003 | 56 | 0.060 |
Why?
| | Recombinant Proteins | 2 | 2018 | 1308 | 0.060 |
Why?
| | Macrophages | 1 | 2011 | 1324 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2011 | 2275 | 0.060 |
Why?
| | Postprandial Period | 1 | 2004 | 96 | 0.060 |
Why?
| | Osmolar Concentration | 3 | 2001 | 185 | 0.060 |
Why?
| | Stroke | 2 | 2011 | 1047 | 0.060 |
Why?
| | Up-Regulation | 1 | 2007 | 872 | 0.060 |
Why?
| | Stem Cells | 1 | 2008 | 559 | 0.060 |
Why?
| | Mice, Transgenic | 2 | 2019 | 2025 | 0.060 |
Why?
| | RNA, Messenger | 1 | 2011 | 2657 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2011 | 1774 | 0.060 |
Why?
| | Powders | 1 | 2023 | 37 | 0.060 |
Why?
| | Butanols | 1 | 2022 | 8 | 0.060 |
Why?
| | Phenotype | 1 | 2011 | 3003 | 0.060 |
Why?
| | Hypercapnia | 1 | 2023 | 50 | 0.060 |
Why?
| | Electromyography | 3 | 1989 | 326 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2023 | 127 | 0.050 |
Why?
| | Biology | 1 | 2023 | 83 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2436 | 0.050 |
Why?
| | Phenols | 1 | 2023 | 85 | 0.050 |
Why?
| | Rats, Inbred Strains | 3 | 1991 | 394 | 0.050 |
Why?
| | Ganglia, Autonomic | 1 | 2001 | 3 | 0.050 |
Why?
| | Respiratory Function Tests | 2 | 1994 | 526 | 0.050 |
Why?
| | Ischemia | 5 | 1994 | 374 | 0.050 |
Why?
| | Men | 1 | 2001 | 21 | 0.050 |
Why?
| | Tidal Volume | 2 | 1993 | 74 | 0.050 |
Why?
| | Acarbose | 1 | 2021 | 2 | 0.050 |
Why?
| | Lactic Acid | 4 | 1995 | 282 | 0.050 |
Why?
| | Drugs, Chinese Herbal | 1 | 2021 | 14 | 0.050 |
Why?
| | Genotype | 1 | 2007 | 1882 | 0.050 |
Why?
| | Blood Viscosity | 1 | 2001 | 19 | 0.050 |
Why?
| | Neurons, Afferent | 2 | 1993 | 89 | 0.050 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2015 | 2174 | 0.050 |
Why?
| | Clinical Trials as Topic | 2 | 2014 | 969 | 0.050 |
Why?
| | Models, Biological | 2 | 2004 | 1715 | 0.050 |
Why?
| | Thoracic Arteries | 1 | 2000 | 4 | 0.050 |
Why?
| | Cerebrovascular Circulation | 1 | 2023 | 204 | 0.050 |
Why?
| | Hypertrophy | 1 | 2001 | 121 | 0.050 |
Why?
| | Mouth | 1 | 2021 | 74 | 0.050 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 36 | 0.050 |
Why?
| | Mexico | 1 | 2001 | 165 | 0.050 |
Why?
| | Organ Size | 2 | 2016 | 460 | 0.050 |
Why?
| | Thinness | 1 | 2000 | 91 | 0.050 |
Why?
| | Stress, Mechanical | 2 | 2001 | 443 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2005 | 1868 | 0.050 |
Why?
| | Heart Conduction System | 2 | 2000 | 81 | 0.050 |
Why?
| | Rats, Inbred F344 | 2 | 1990 | 245 | 0.050 |
Why?
| | Corticotropin-Releasing Hormone | 2 | 1991 | 77 | 0.050 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 374 | 0.040 |
Why?
| | NADP | 1 | 2019 | 50 | 0.040 |
Why?
| | Head-Down Tilt | 1 | 1999 | 5 | 0.040 |
Why?
| | Myocardial Infarction | 2 | 2005 | 968 | 0.040 |
Why?
| | Antihypertensive Agents | 1 | 2022 | 437 | 0.040 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2018 | 22 | 0.040 |
Why?
| | Prevalence | 2 | 2005 | 2326 | 0.040 |
Why?
| | Hyperinsulinism | 1 | 2019 | 107 | 0.040 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 25 | 0.040 |
Why?
| | Biological Transport | 1 | 2019 | 382 | 0.040 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 1998 | 82 | 0.040 |
Why?
| | Acute Disease | 1 | 2000 | 940 | 0.040 |
Why?
| | Mathematics | 2 | 1996 | 103 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 1998 | 79 | 0.040 |
Why?
| | Automation | 1 | 1997 | 77 | 0.040 |
Why?
| | Echocardiography | 2 | 2005 | 556 | 0.040 |
Why?
| | Rotarod Performance Test | 1 | 2017 | 17 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 1998 | 140 | 0.040 |
Why?
| | Cell Respiration | 1 | 2017 | 76 | 0.040 |
Why?
| | Splanchnic Circulation | 2 | 1999 | 12 | 0.040 |
Why?
| | Adenylate Kinase | 1 | 2016 | 29 | 0.040 |
Why?
| | Weight Lifting | 3 | 1988 | 30 | 0.040 |
Why?
| | Muscle Development | 1 | 1997 | 102 | 0.040 |
Why?
| | Myoblasts | 1 | 2017 | 75 | 0.040 |
Why?
| | Body Height | 1 | 1997 | 187 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2017 | 156 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2019 | 2513 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 228 | 0.030 |
Why?
| | Tissue Plasminogen Activator | 1 | 1998 | 231 | 0.030 |
Why?
| | Resilience, Psychological | 1 | 2017 | 97 | 0.030 |
Why?
| | Pain | 2 | 1992 | 735 | 0.030 |
Why?
| | Cholesterol, HDL | 3 | 1984 | 198 | 0.030 |
Why?
| | Menstruation | 1 | 1995 | 36 | 0.030 |
Why?
| | Indicator Dilution Techniques | 1 | 1995 | 12 | 0.030 |
Why?
| | Haplorhini | 1 | 2015 | 62 | 0.030 |
Why?
| | Receptors, Leptin | 1 | 2015 | 27 | 0.030 |
Why?
| | Autonomic Fibers, Postganglionic | 1 | 1994 | 1 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 310 | 0.030 |
Why?
| | Spectrophotometry | 1 | 1994 | 52 | 0.030 |
Why?
| | Median Nerve | 1 | 1994 | 21 | 0.030 |
Why?
| | Neurotransmitter Agents | 1 | 1995 | 76 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2015 | 280 | 0.030 |
Why?
| | Homozygote | 1 | 2015 | 190 | 0.030 |
Why?
| | Dilatation, Pathologic | 1 | 2014 | 56 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 2874 | 0.030 |
Why?
| | Gated Blood-Pool Imaging | 1 | 1994 | 6 | 0.030 |
Why?
| | Heterozygote | 1 | 2015 | 262 | 0.030 |
Why?
| | Point Mutation | 1 | 2015 | 228 | 0.030 |
Why?
| | Health | 1 | 2014 | 81 | 0.030 |
Why?
| | Educational Measurement | 1 | 2016 | 289 | 0.030 |
Why?
| | Propranolol | 3 | 2001 | 54 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2013 | 18 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2016 | 369 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 455 | 0.030 |
Why?
| | eIF-2 Kinase | 1 | 2013 | 26 | 0.030 |
Why?
| | Microbiota | 1 | 2021 | 656 | 0.030 |
Why?
| | Reflex, Stretch | 1 | 1993 | 9 | 0.030 |
Why?
| | Heart-Lung Transplantation | 1 | 1993 | 11 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2015 | 280 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 870 | 0.030 |
Why?
| | Denervation | 1 | 1993 | 21 | 0.030 |
Why?
| | Endoribonucleases | 1 | 2013 | 64 | 0.030 |
Why?
| | Venous Pressure | 1 | 1992 | 7 | 0.030 |
Why?
| | Chemoreceptor Cells | 1 | 1993 | 54 | 0.030 |
Why?
| | Synaptic Transmission | 1 | 1995 | 239 | 0.030 |
Why?
| | Age of Onset | 1 | 2014 | 467 | 0.030 |
Why?
| | Skin Temperature | 1 | 1992 | 17 | 0.030 |
Why?
| | Fingers | 1 | 2013 | 83 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 565 | 0.030 |
Why?
| | Tissue Distribution | 1 | 1993 | 334 | 0.030 |
Why?
| | Ovariectomy | 1 | 2012 | 124 | 0.030 |
Why?
| | Task Performance and Analysis | 1 | 1992 | 164 | 0.020 |
Why?
| | Renal Circulation | 1 | 1991 | 75 | 0.020 |
Why?
| | Cardiography, Impedance | 1 | 1991 | 6 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2013 | 241 | 0.020 |
Why?
| | Cell Line | 1 | 2017 | 2707 | 0.020 |
Why?
| | Inspiratory Capacity | 1 | 1990 | 2 | 0.020 |
Why?
| | Metformin | 1 | 2014 | 295 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 363 | 0.020 |
Why?
| | Acupuncture Therapy | 1 | 1990 | 19 | 0.020 |
Why?
| | Blood Pressure Monitors | 1 | 1989 | 2 | 0.020 |
Why?
| | Arousal | 1 | 1991 | 157 | 0.020 |
Why?
| | Anorexia Nervosa | 1 | 1990 | 74 | 0.020 |
Why?
| | Lipoproteins | 2 | 1988 | 162 | 0.020 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2001 | 301 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2011 | 828 | 0.020 |
Why?
| | Total Lung Capacity | 1 | 1988 | 33 | 0.020 |
Why?
| | Menstrual Cycle | 1 | 2009 | 113 | 0.020 |
Why?
| | Fever | 1 | 1990 | 283 | 0.020 |
Why?
| | Saponins | 1 | 1988 | 7 | 0.020 |
Why?
| | Postoperative Period | 1 | 1989 | 309 | 0.020 |
Why?
| | Neural Inhibition | 1 | 1989 | 160 | 0.020 |
Why?
| | Digoxin | 1 | 1988 | 27 | 0.020 |
Why?
| | Child | 3 | 1997 | 19129 | 0.020 |
Why?
| | Ultrasonography, Doppler, Duplex | 1 | 2007 | 39 | 0.020 |
Why?
| | Hormones | 1 | 1988 | 135 | 0.020 |
Why?
| | Adrenergic Fibers | 1 | 1987 | 4 | 0.020 |
Why?
| | Pain Management | 1 | 1990 | 294 | 0.020 |
Why?
| | Depressive Disorder | 1 | 1990 | 333 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2009 | 1094 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2013 | 1055 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 210 | 0.020 |
Why?
| | Environmental Exposure | 1 | 1991 | 405 | 0.020 |
Why?
| | Fatigue | 1 | 1988 | 297 | 0.020 |
Why?
| | Forced Expiratory Volume | 1 | 1988 | 520 | 0.020 |
Why?
| | Down-Regulation | 1 | 2009 | 627 | 0.020 |
Why?
| | Kidney Diseases | 1 | 2011 | 439 | 0.020 |
Why?
| | Heart Block | 1 | 1986 | 37 | 0.020 |
Why?
| | Syncope | 1 | 1986 | 32 | 0.020 |
Why?
| | Blood Proteins | 1 | 1988 | 248 | 0.020 |
Why?
| | Peptide Fragments | 1 | 1990 | 702 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1244 | 0.020 |
Why?
| | Feedback | 1 | 2005 | 153 | 0.020 |
Why?
| | DNA Methylation | 1 | 2009 | 503 | 0.020 |
Why?
| | Anabolic Agents | 1 | 1984 | 12 | 0.020 |
Why?
| | Affect | 1 | 2007 | 240 | 0.020 |
Why?
| | Dogs | 1 | 2005 | 371 | 0.020 |
Why?
| | Hemostatics | 1 | 2005 | 50 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2011 | 2680 | 0.020 |
Why?
| | Drug Tolerance | 1 | 1984 | 78 | 0.020 |
Why?
| | Arrhythmias, Cardiac | 1 | 1986 | 277 | 0.010 |
Why?
| | C-Peptide | 1 | 1984 | 137 | 0.010 |
Why?
| | Methods | 1 | 1983 | 67 | 0.010 |
Why?
| | Work Capacity Evaluation | 1 | 2002 | 13 | 0.010 |
Why?
| | Androgens | 1 | 1984 | 167 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1983 | 182 | 0.010 |
Why?
| | Motivation | 1 | 2007 | 506 | 0.010 |
Why?
| | Heart Arrest | 1 | 1986 | 291 | 0.010 |
Why?
| | Wrestling | 1 | 1982 | 4 | 0.010 |
Why?
| | Gymnastics | 1 | 1982 | 21 | 0.010 |
Why?
| | Efferent Pathways | 2 | 1992 | 16 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 144 | 0.010 |
Why?
| | Renal Veins | 1 | 1999 | 12 | 0.010 |
Why?
| | Femur | 1 | 2001 | 199 | 0.010 |
Why?
| | Jugular Veins | 1 | 1999 | 47 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2000 | 180 | 0.010 |
Why?
| | Oscillometry | 1 | 1998 | 34 | 0.010 |
Why?
| | Metabolic Clearance Rate | 1 | 1998 | 113 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2001 | 521 | 0.010 |
Why?
| | Self Concept | 1 | 1996 | 215 | 0.010 |
Why?
| | Injections, Intraventricular | 1 | 1990 | 73 | 0.010 |
Why?
| | Pain Measurement | 1 | 1992 | 469 | 0.010 |
Why?
| | Pancreatic Hormones | 1 | 1988 | 3 | 0.010 |
Why?
| | Thyroid Hormones | 1 | 1988 | 55 | 0.010 |
Why?
| | Cardenolides | 1 | 1988 | 1 | 0.010 |
Why?
| | Growth Hormone | 1 | 1988 | 108 | 0.010 |
Why?
| | Glycerol | 1 | 1988 | 88 | 0.000 |
Why?
| | Fatty Acids, Nonesterified | 1 | 1988 | 167 | 0.000 |
Why?
| | Insulin-Like Growth Factor I | 1 | 1988 | 287 | 0.000 |
Why?
| | Differential Threshold | 1 | 1985 | 5 | 0.000 |
Why?
| | Maximal Voluntary Ventilation | 1 | 1985 | 7 | 0.000 |
Why?
| | Bicycling | 1 | 1985 | 77 | 0.000 |
Why?
| | Risk | 1 | 1987 | 853 | 0.000 |
Why?
| | Action Potentials | 1 | 1987 | 420 | 0.000 |
Why?
| | Ammonia | 1 | 1984 | 65 | 0.000 |
Why?
| | Testosterone | 1 | 1984 | 351 | 0.000 |
Why?
| | Substance-Related Disorders | 1 | 1984 | 971 | 0.000 |
Why?
|
|
Seals's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|